RxDoctor Payments Data

Shnehal Patel, MD

Neurology · Grove City, OHNPI 1972820447

Payments from drug & device makers

$198,174in general payments, 2019–2025

Across 360 payments — averaging $550.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$127K
  • MDD US Operations, LLC$22K
  • Kyowa Kirin, Inc.$15K
  • Amneal Pharmaceuticals LLC$10K
  • Adamas Pharmaceuticals, Inc.$8K
  • Neurocrine Biosciences, Inc.$6K
  • plus $10K from 9 others

What the payments were for

  • Consulting fees$6,6753%
  • Speaking & faculty fees$163,07682%
  • Travel & lodging$20,92011%
  • Food & beverage$6,1703%
  • Education$1,3331%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$198,174 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$233,759
Medicare patients
282
Services billed
20,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate31$241,544
AustedoDeutetrabenazine15$188,616
Austedo XrDeutetrabenazine23$157,350
GocovriAmantadine Hcl14$42,819
Carbidopa-LevodopaCarbidopa/Levodopa623$22,955
RytaryCarbidopa/Levodopa27$15,771
Carbidopa-Levodopa ErCarbidopa/Levodopa218$12,643
Aimovig AutoinjectorErenumab-Aooe12$8,868
Rivastigmine44$8,290
Primidone199$5,141
Droxidopa12$3,328
Selegiline Hcl16$1,773
AmantadineAmantadine Hcl35$1,743
Ropinirole ErRopinirole Hcl12$1,228
Propranolol Hcl ErPropranolol Hcl34$1,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$273$345,96638 claims
Neurocrine Biosciences, Inc.Ingrezza$5,760$241,54431 claims
MDD US Operations, LLCGocovri$22,386$42,81914 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$10,324$16,28345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 702 neurology providers in Ohio.

Other neurology in Grove City

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →